Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitotane in Metastatic Castration-Resistant Prostate Cancer
NCT02057237Phase 1Completed
- Sponsor
- University Health Network
- Start
- Sep 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mitotane in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University Health Network. Primary endpoint: Proportion of Patients Maintained on Mitotane After 12 Consecutive Weeks of Therapy at 12 weeks. Started Sep 2013; status: completed.
02
Drugs
mitotane
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02057237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057237.